Viatris Inc. -B (09887.HK): The first patient in the LBL-034 Phase II trial successfully treated.

date
26/08/2025
Zhithong Financial App News, Viva Biotech-B (09887.HK) announced that the LBL-034 (GPRC5D/CD3 Bispecific Antibody) Phase I data is impressive, and the first patient in the Phase II trial has successfully received treatment. This signifies a milestone achievement in the clinical research of the LBL-034 group, laying a solid foundation for advancing subsequent clinical trials.